SPOTLIGHT: FDA wants more Arixtra info

The FDA has asked for more information from GlaxoSmithKline regarding its application to use the anti-clotting drug Arixtra for unstable angina. GSK didn't elaborate on what the agency was looking for, but said it would cooperate. Release | Report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.